組蛋白去乙醯酶1 (EC 188.8.131.52) :開發中產品分析
Histone Deacetylase 1 (HDAC1 or EC 184.108.40.206) - Drugs In Development, 2021
|出版商||Global Markets Direct||商品編碼||363131|
|出版日期||內容資訊||英文 191 Pages
|組蛋白去乙醯酶1 (EC 220.127.116.11) :開發中產品分析 Histone Deacetylase 1 (HDAC1 or EC 18.104.22.168) - Drugs In Development, 2021|
|出版日期: 2021年08月31日||內容資訊: 英文 191 Pages||
本報告提供組蛋白去乙醯酶1 (EC 22.214.171.124)的開發情形調查分析，提供您開發中產品的概要，臨床實驗的各階段產品概要，主要企業簡介，藥物簡介，開發中產品的最新趨勢，最新消息和新聞稿等系統性資訊。
According to the recently published report 'Histone Deacetylase 1 - Drugs In Development, 2021'; Histone Deacetylase 1 (HDAC1 or EC 126.96.36.199) pipeline Target constitutes close to 39 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 1 (HDAC1 or EC 188.8.131.52) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
The report 'Histone Deacetylase 1 - Drugs In Development, 2021' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7, 1, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Melanoma, Diffuse Large B-Cell Lymphoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Follicular Lymphoma, Colorectal Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mycosis Fungoides, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), HER2- Breast Cancer, Liver Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified B-Cell Lymphomas, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anal Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Rhabdomyosarcoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.